Tonix Pharmaceuticals Enters into Exclusive Worldwide Licensing Agreement with OyaGen to Develop Antiviral SARS-CoV-2 Inhibitor, TNX-3500, for the Treatment of COVID-19

NEXT STORY
Arcellx Announces Executive Appointments
PREV STORY
Global Travel Vaccines Market Report 2021: Market Reached a Value of $2.94 Billion in 2020 – Forecast to 2026
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Tonix Pharmaceuticals Enters into Exclusive Worldwide Licensing Agreement with OyaGen to Develop Antiviral SARS-CoV-2 Inhibitor, TNX-3500, for the Treatment of COVID-19

NEXT STORY
Arcellx Announces Executive Appointments
PREV STORY
Global Travel Vaccines Market Report 2021: Market Reached a Value of $2.94 Billion in 2020 – Forecast to 2026
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Centrexion Therapeutics Announces Publication of Phase 2 Efficacy Data on CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain in Arthritis & Rheumatology

author_avatar
NASDAQ Market News

Press Release Biocartis Group NV: Biocartis to Host Webcast for Announcement 2019 Financial Results on 5 March 2020

author_avatar
NASDAQ Market News

miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd

author_avatar
NASDAQ Market News